CL King Reiterates Buy Rating on Boston Scientific (BSX)

CL King analyst Kristen Stewart reiterated a Buy rating and $90.00 price target on Boston Scientific (NYSE: BSX)

The analyst comments "Boston Scientific (BSX) reported 3Q24 results that came in well above consensus expectations. We expect the stock to react favorably to the results. BSX will host a conference call today at 8:00am ET to discuss the results and outlook. We maintain our Buy rating. We believe the stock should react favorably to the Q3 results. Our $90 price target is based on a P/E multiple of 33x our current FY25 EPS estimate of $2.71."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $87.45 yesterday.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Axis Capital Limited Downgrades Nippon Life India Asset Management Ltd (NAM:IN) to Add (2)
• BNP Paribas Exane Upgrades Holcim Ltd (HOLN:SW) to Outperform